[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"headache-disorders-secondary\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:headache-disorders-secondary":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,59,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":44,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100619142","hypersensitivity-to-amylin-in-post-traumatic-headache-100619142",false,"NCT07340775","Hypersensitivity to Amylin in Post-Traumatic Headache","Hypersensitivity to Amylin in Post-Traumatic Headache: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* History of persistent headache attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)\n* ≥ 4 monthly headache days on average across the 3 months prior to screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures\n\nExclusion Criteria:\n\n* \\> 1 mild traumatic injury to the head\n* History of any primary or secondary headache disorder prior to mild traumatic injury to the head (except for infrequent episodic tension-type headache)\n* History of moderate or severe injury to the head\n* History of whiplash injury\n* History of craniotomy\n* History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) than, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion\n* Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start\n* Baseline headache intensity of \\>3 on an 11-point numeric rating scale (0 being no headache, 10 being the worst imaginable headache)\n* Baseline migraine-like headache or self-reported baseline headache that mimics the subjects' usual migraine-like headache","ALL","18 Years","65 Years",{"count":20,"type":21},21,"ESTIMATED","INTERVENTIONAL",[24],"NA","Pramlintide is a peptide analogue of human amylin which is a vasoactive substance involved in the pathogenesis of headache. This study investigates whether pramlintide induces migraine-like headache in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43],"Headache Disorders, Secondary","Brain Diseases","Headache Disorders","Nervous System Diseases","Central Nervous System Diseases","Neurologic Manifestations","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Post-Traumatic Headache","Pain","Peptide Hormones","Hormones","Hormones, Hormone Substitutes, and Hormone Antagonists","Peptides","Amino Acids, Peptides, and Proteins","Amylin","Pramlintide",[45,36,42],"Post-traumatic headache","NOT_YET_RECRUITING","2026-01-05",{"date":49,"type":50},"2026-01-14","ACTUAL",{"date":52,"type":21},"2026-02",{"date":54,"type":21},"2028-12",{"name":56,"class":57},"Danish Headache Center","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":16,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":71,"studyType":72,"phases":4,"briefSummary":73,"conditions":74,"keywords":82,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":58},"100434650","china-headache-and-vertigo-registry-study-100434650","NCT04939922","China Headache and Vertigo Registry Study","CHRS","Inclusion Criteria:\n\n* Written informed consent and participant privacy information (eg, Written Authorization for Use and Release of Health and Research Study Information) obtained from the participant prior to initiation of any study-specific procedures.\n* Male or female participants ages 4 to 99 years.\n* Headache patients meeting the diagnostic criteria for ICHD-3, including primary headaches such as migraine and tension tension-type headaches, secondary headaches.\n* Patients who meet the headache diagnosis in the ICHD-3 appendix (including vestibular migraine).\n\nExclusion Criteria:\n\n* Patients who were unable to complete scales such as headache diary.\n* Patients denied or unable to be admitted for long-term follow-up.",true,"4 Years","99 Years",{"count":70,"type":21},10000,"30 Years","OBSERVATIONAL","In the Chinese Headache and Vertigo Registration Study, patients aged 4-99 years with headache (primary headache and secondary headache such as migraine and tension type headache), vertigo (vertigo diseases such as vestibular migraine) and chronic pain (fibromyalgia and other diseases) were collected. The biomarkers, imaging features, right-to-left shunt of the heart (lung), genetic characteristics, treatment, and outcome (in relation to other diseases) of headache-related diseases were studied, and long-term follow-up was planned.",[75,27,76,77,78,79,80,81],"Headache Disorders, Primary","Migraine","Tension-Type Headache","Cluster Headache","Vertigo, Constant","Vestibular Migraine","Fibromyalgia",[76,29,83,80,81],"Vertigo","RECRUITING","2025-07-22",{"date":87,"type":50},"2025-07-25",{"date":89,"type":50},"2017-06-12",{"date":91,"type":21},"2050-12-12",{"name":93,"class":57},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":66,"sex":16,"minAge":67,"maxAge":68,"enrollmentInfo":102,"targetDuration":104,"studyType":72,"phases":4,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":58},"100471387","international-headache-registry-study-100471387","NCT05418218","International Headache Registry Study","International Headache and Vertigo Registration Study","IHRS","Inclusion Criteria:\n\nThe following are requirements for entry into the study:\n\n1. Written informed consent and participant privacy information (eg, Written Authorization for Use and Release of Health and Research Study Information) obtained from the participant prior to initiation of any study-specific procedures.\n2. Male or female participants ages 4 to 99 years, inclusive, at Visit 1.\n3. Headache patients meeting the diagnostic criteria for ICHD-3, including primary headaches such as migraine and tension tension-type headaches, secondary headaches, and patients who meet the headache diagnosis in the ICHD-3 appendix (including vestibular migraine).\n\nExclusion Criteria:\n\n1. Patients who were unable to complete scales such as headache diary.\n2. Patients denied or unable to be admitted for long-term follow-up.",{"count":103,"type":21},200000,"60 Years","In the International Headache and Vertigo Registration Study, patients aged 4-99 years with headache (primary headache and secondary headache such as migraine and tension type headache), vertigo (vertigo diseases such as vestibular migraine) and chronic pain (fibromyalgia and other diseases) were collected. The biomarkers, imaging features, right-to-left shunt of the heart (lung), genetic characteristics, treatment, and outcome (in relation to other diseases) of headache-related diseases were studied, and long-term follow-up was planned.",[75,27,76,77,83,80,81],[76,29,83,80,81],"2025-05-19",{"date":110,"type":50},"2025-05-23",{"date":112,"type":50},"2021-07-12",{"date":114,"type":21},"2082-12-31",{"name":93,"class":57}]